Company

Jiangsu Vcare's VC005 JAK1 Inhibitor Wins CDE IND Approval for Seborrheic Dermatitis – Fourth Topical Indication for Next‑Generation Molecule
Clinical trial approval / initiationVcare PharmaTech

Jiangsu Vcare’s VC005 JAK1 Inhibitor Wins CDE IND Approval for Seborrheic Dermatitis – Fourth Topical Indication for Next‑Generation Molecule

Jiangsu Vcare PharmaTech Co., Ltd. announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval for VC005 topical…

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CanSino BiologicsHKG: 6185

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

CancerClinical trial approval / initiation

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma

BiosimilarsHenlius Biotech

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Ark BiopharmaceuticalClinical trial approval / initiation

Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV

Show More